High dose – Communicable Diseases Research

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2

Article

Published on 2022-11-082022-11-15
Journal: EMBO Molecular Medicine [Category] SARS, 변종, 유전자 메커니즘, 진단,

[키워드] ACE2 Administered administration ameliorated Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibody betacoronaviruses bind catalytic activity catalytically active Clinical use COVID-19 decoy demonstrated effective entry receptor High dose Host increased survival Infection Inflammation inoculated intravenous intravenously K18-hACE2 mice Loss Lung injury mechanism neutralization potency neutralize omicron Omicron variant persist PROTECT receptor reduced sACE2 SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants shown substrate target the SARS-CoV-2 therapeutic efficacy therapeutic potential Treatment virus
[DOI] 10.15252/emmm.202216109 PMC 바로가기

Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial

Article

Published on 2022-11-012022-11-15
Journal: International Journal of Infectious Diseases [Category] 진단,

SARS-CoV-2 Infection Causes Hyperglycemia in Cats

Article

Published on 2022-11-012022-11-15
Journal: The Journal of Infectious Diseases [Category] SARS, 치료기술, 치료제,

COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis

Research article

Published on 2022-10-012022-10-05
Journal: Seminars in arthritis and rheumatism [Category] 변종,

[키워드] 1:1 Acute kidney injury acute respiratory distress adjust African American AKI Analysis ARDS association Black race Cancer patients cohort analysis confounders Control controls COVID-19 database dermatomyositis determine develop Disease activity drug Gender General population glucocorticoid heterogeneous nature High dose higher odd hospitalisation ICU admission identify ILD Immunosuppressant immunosuppressive individual Infection Interstitial lung disease lower risk male mechanical ventilation Mortality neoplasm Neoplasms outcome outcomes Patient patients with COVID-19 Precaution receiving renal replacement therapy required retrieved retrospective data rheumatic disease risk RRT score Sepsis severe COVID-19 Severe COVID-19 Infection severity of COVID-19 stroke subgroup analysis syndrome therapy Treatment Venous Thromboembolism VTE was used with COVID-19
[DOI] 10.1016/j.semarthrit.2022.152034 [Article Type] Research article

SARS-CoV-2 spike protein aggregation is triggered by bacterial lipopolysaccharide

Article

Published on 2022-10-012022-11-16
Journal: Febs Letters [Category] COVID19(2023년), SARS, 변종, 치료기술,

The effects of high dose vitamin D supplementation as a nutritional intervention strategy on biochemical and inflammatory factors in adults with COVID-19: Study protocol for a randomized controlled trial

COVID-19 성인의 생화학적 및 염증 인자에 대한 영양 중재 전략으로서 고용량 비타민 D 보충제의 효과: 무작위 대조 시험을 위한 연구 프로토콜

Article

Published on 2022-09-012022-09-11
Journal: Nutrition and health [Category] 바이오마커, 임상,

[키워드] All participant All participants Analysis baseline biochemical blood count both groups CBC changes in chest CT scan classification clinical outcomes complete blood count conducted confounders control group covariance COVID-19 Descriptive statistics diagnosis of COVID-19 double-blind duration of hospitalization Effect erythrocyte sedimentation erythrocyte sedimentation rate ESR Evidence followed by gel heart High dose hospitalized COVID-19 patients hs-CRP Imam in both groups Inflammation Inflammatory factor Inflammatory marker inflammatory markers intervention group Iran Laboratory life liver Mashhad mortality rate New York nutritional intervention parameter participant Patient performed Placebo protocol Quality of life randomization Randomized Randomized controlled trial receive recorded renal Reza risk factor RT-PCR sedimentation rate serum serum vitamin D shown study period Trial undergo Vitamin D Vitamin D supplementation with COVID-19
[DOI] 10.1177/02601060221082384 PMC 바로가기 [Article Type] Article

Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults

비활성화된 전체 바이러스 면역증강제 COVID-19 백신 VLA2001의 안전성 및 면역원성: 건강한 성인을 대상으로 한 무작위, 용량 증량, 이중 맹검 1/2상 임상 시험

Clinical Trial

Published on 2022-09-012022-09-12
Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 임상, 진단,

[키워드] Adjuvanted vaccine binding clinical development clinical trial conducted convalescent sera coronavirus COVID-19 COVID-19 vaccine CpG CpG 1018 dose Dose escalation dose-escalation double-blind evaluate expressing Frequency geometric mean titre GMT groups headache healthy High dose high-dose group highest dose IFN-γ IgG immunogenicity inactivated Inactivated vaccine injection Local medium N protein neutralizing antibody Open-label optimal dose outcome participant Phase 3 primary immunogenicity priming Randomized randomized trial RBD-binding IgG RBD-binding IgG antibody reactive recruited Registered reported S protein S protein binding IgG antibody Safety SARS-CoV-2 SARS-CoV-2 neutralizing antibody second vaccination severity significantly significantly higher statistically systemic reaction T-cell tested titre Tolerability vaccination Vaccine VLA2001 was selected Whole-virus vaccine.
[DOI] 10.1016/j.jinf.2022.06.009 PMC 바로가기 [Article Type] Clinical Trial

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

Research

Published on 2022-08-302022-10-05
Journal: Nature Communications [Category] SARS, 임상, 치료기술, 치료법, 치료제,

Ferrets as a model for tuberculosis transmission

Article

Published on 2022-08-162022-11-15
Journal: Frontiers in Cellular and Infection Microbiology [Category] SARS, 진단,

Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial

Randomized Controlled Trial

Published on 2022-08-042022-10-04
Journal: The European Respiratory Journal [Category] Fulltext, SARS, 임상,

[키워드] 1:1 28-day mortality 95% CI age assigned Clinical improvement clinical status clinical trial Controlled trial coronavirus disease COVID-19 death demonstrated Dexamethasone discharged Effect Efficacy enrolled Evidence High dose High-dose high-dose group hospitalised hospitalised COVID-19 patient hospitalised patient low dose low-dose male moderate no significant difference Open-label outcome oxygen Oxygen therapy Patient performed Pneumonia Primary outcome randomisation randomised Randomly receive reduced secondary seven-point ordinal scale severe COVID-19 Time to recovery worsening
[DOI] 10.1183/13993003.02518-2021 PMC 바로가기 [Article Type] Randomized Controlled Trial